Skip to main content

Dystrophic Epidermolysis Bullosa

6
Pipeline Programs
5
Companies
9
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
4
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Krystal Biotech
Krystal BiotechPA - Pittsburgh
6 programs
1
3
KB803Phase 31 trial
Open Label Topical Beremagene GeperpavecPhase 31 trial
Topical Beremagene GeperpavecPhase 31 trial
Topical beremagene geperpavecPhase 1/21 trial
Long-Term Follow-up ProtocolN/A1 trial
+1 more programs
Active Trials
NCT04917887Recruiting50Est. May 2028
NCT04214002Withdrawn0Est. Feb 2020
NCT03536143Completed12Est. Nov 2019
+3 more trials
Castle Creek Biosciences
1 program
1
D-FiPhase 31 trial
Active Trials
NCT06892639Active Not Recruiting32Est. Feb 2042
Aegle Therapeutics
1 program
1
AGLE-102Phase 1/21 trial
Active Trials
NCT04173650Recruiting8Est. Mar 2026
Tissue Repair
Tissue RepairAustralia - Sydney
1 program
Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis BullosaN/A
Lotus Pharmaceuticals
Lotus PharmaceuticalsTaiwan - Taipei
1 program
Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis BullosaN/A1 trial
Active Trials
NCT01768026Withdrawn0Est. Sep 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Krystal BiotechKB803
Castle Creek BiosciencesD-Fi
Krystal BiotechOpen Label Topical Beremagene Geperpavec
Krystal BiotechTopical Beremagene Geperpavec
Aegle TherapeuticsAGLE-102
Krystal BiotechTopical beremagene geperpavec
Krystal BiotechLong-Term Follow-up Protocol
Krystal BiotechThe Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)
Lotus PharmaceuticalsProspective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa

Clinical Trials (9)

Total enrollment: 196 patients across 9 trials

NCT07016750Krystal BiotechKB803

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

Start: Jun 2025Est. completion: Dec 202616 patients
Phase 3Recruiting
NCT06892639Castle Creek BiosciencesD-Fi

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

Start: Mar 2025Est. completion: Feb 204232 patients
Phase 3Active Not Recruiting
NCT04917874Krystal BiotechOpen Label Topical Beremagene Geperpavec

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Start: May 2021Est. completion: Jul 202347 patients
Phase 3Completed
NCT04491604Krystal BiotechTopical Beremagene Geperpavec

Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB

Start: Aug 2020Est. completion: Jan 202231 patients
Phase 3Completed
NCT04173650Aegle TherapeuticsAGLE-102

MSC EVs in Dystrophic Epidermolysis Bullosa

Start: Aug 2024Est. completion: Mar 20268 patients
Phase 1/2Recruiting
NCT03536143Krystal BiotechTopical beremagene geperpavec

A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients

Start: May 2018Est. completion: Nov 201912 patients
Phase 1/2Completed
NCT04917887Krystal BiotechLong-Term Follow-up Protocol

Long-Term Follow-up Protocol

Start: May 2021Est. completion: May 202850 patients
N/ARecruiting
NCT04214002Krystal BiotechThe Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)

The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Start: Jan 2020Est. completion: Feb 20200
N/AWithdrawn
NCT01768026Lotus PharmaceuticalsProspective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa

Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa

Start: Feb 2013Est. completion: Sep 20140
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 196 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.